Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Province, PR China.
Medicine (Baltimore). 2020 Dec 18;99(51):e23698. doi: 10.1097/MD.0000000000023698.
Allergic rhinitis (AR) is a non-infectious chronic nasal mucosal disease mediated mainly by IgE, which affects 40% of the global population and has a recurrence rate of more than 50%. The modified Yupingfeng formula (MYPFF) is widely used in the treatment of allergic rhinitis in China. However, there is no evidence-based medical evidence for the efficacy and safety of MYPFF in the treatment of allergic rhinitis.
Database as China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Scientific Journal Database (VIP database), Wan-Fang Database, the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, and Web of Science will be searched for relevant literature from inception to September 2020. Data extraction will be performed on the obtained literature. Then RevMan V.5.3 will be used for the assessment of the risk of bias and data synthesis.
The results will be published in a peer-reviewed journal.
The conclusion of the study will provide an evidence to efficacy and safety of MYPFF in treating allergic rhinitis, which will be of significant meaning for further research and clinical practice.
10.17605/OSF.IO/RV9P4.
变应性鼻炎（AR）是一种主要由 IgE 介导的非传染性慢性鼻黏膜疾病，影响全球 40%的人口，复发率超过 50%。玉屏风配方（MYPFF）在我国广泛用于治疗变应性鼻炎。然而，对于 MYPFF 治疗变应性鼻炎的疗效和安全性，尚无循证医学证据。
检索中国知网、中国生物医学文献数据库、中国科学引文数据库（VIP 数据库）、万方数据库、Cochrane 中心对照试验注册库（CENTRAL）、PubMed、EMBASE 和 Web of Science 数据库，检索时间为建库至 2020 年 9 月。对获得的文献进行数据提取，然后使用 RevMan V.5.3 评估偏倚风险和数据合成。
研究结果将发表在同行评议的期刊上。
本研究的结论将为 MYPFF 治疗变应性鼻炎的疗效和安全性提供证据，对进一步的研究和临床实践具有重要意义。
OSF 注册号：10.17605/OSF.IO/RV9P4。
